Matches in DBpedia 2016-04 for { ?s ?p "Lenvatinib (E7080; trade name Lenvima) is a multi-kinase inhibitor developed by Eisai Co. It inhibits both VEGFR2 and VEGFR3 kinases.Lenvatinib was granted orphan drug status for the treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013.In February 2015, the FDA granted approval to lenvatinib for treatment of progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Lenvatinib comment "Lenvatinib (E7080; trade name Lenvima) is a multi-kinase inhibitor developed by Eisai Co. It inhibits both VEGFR2 and VEGFR3 kinases.Lenvatinib was granted orphan drug status for the treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013.In February 2015, the FDA granted approval to lenvatinib for treatment of progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).".
- Q6523413 comment "Lenvatinib (E7080; trade name Lenvima) is a multi-kinase inhibitor developed by Eisai Co. It inhibits both VEGFR2 and VEGFR3 kinases.Lenvatinib was granted orphan drug status for the treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013.In February 2015, the FDA granted approval to lenvatinib for treatment of progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).".